Credit: Shutterstock photoCEO of Biomarin Pharmaceutical Inc ( BMRN ) Jean Jacques Bienaime sold --…,……… shares of BMRN on -…/-8/-…-6 at an average price of $8-.' a share. The total sale was $9.8 million.
Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse. Biomarin Pharmaceutical Inc has a market cap of $-'.-6 billion; its shares were traded at around $8….5- with and P/S ratio of -'.'6.
CEO Recent Trades:
- CEO Jean Jacques Bienaime sold --…,……… shares of BMRN stock on -…/-8/-…-6 at the average price of $8-.'. The price of the stock has decreased by ….96% since.
- CEO Jean Jacques Bienaime sold 4-,666 shares of BMRN stock on -…/-7/-…-6 at the average price of $84.'9. The price of the stock has decreased by 4.59% since.
- CEO Jean Jacques Bienaime sold 64,--5 shares of BMRN stock on -…/-4/-…-6 at the average price of $86.96. The price of the stock has decreased by 7.4-% since.
For the complete insider trading history of BMRN, click here
.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
